Patient characteristics at initial diagnosis
| Characteristics at diagnosis . | Data (n = 29) . |
|---|---|
| Age, median (range) | 15 (7-20) |
| Female (%) | 12 (41) |
| Male (%) | 17 (59) |
| Disease stage at diagnosis, n (%) | |
| II | 15 (52) |
| III | 7 (24) |
| IV | 5 (17) |
| Unknown | 2 (7) |
| Baseline disease characteristics, n (%) | |
| Bulk | 14 (48) |
| B symptoms | 18 (62) |
| Extranodal disease | 4 (14) |
| Frontline treatment, n (%) | |
| ABVE-PC ×4-6 | 15 (52) |
| OEPA-COPDAC/OPPA-COPP | 4 (14) |
| ABVD/A-AVD ×6 | 3 (10) |
| ABVD ×3-4 | 2 (7) |
| Other | 5 (17) |
| Radiation therapy | 13 (45) |
| Characteristics at diagnosis . | Data (n = 29) . |
|---|---|
| Age, median (range) | 15 (7-20) |
| Female (%) | 12 (41) |
| Male (%) | 17 (59) |
| Disease stage at diagnosis, n (%) | |
| II | 15 (52) |
| III | 7 (24) |
| IV | 5 (17) |
| Unknown | 2 (7) |
| Baseline disease characteristics, n (%) | |
| Bulk | 14 (48) |
| B symptoms | 18 (62) |
| Extranodal disease | 4 (14) |
| Frontline treatment, n (%) | |
| ABVE-PC ×4-6 | 15 (52) |
| OEPA-COPDAC/OPPA-COPP | 4 (14) |
| ABVD/A-AVD ×6 | 3 (10) |
| ABVD ×3-4 | 2 (7) |
| Other | 5 (17) |
| Radiation therapy | 13 (45) |
A-AVD, brentuximab vedotin, doxorubicin, vinblastine, dacarbazine; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; COPDAC, cyclophosphamide, vincristine, prednisone, dacarbazine; COPP, cyclophosphamide, vincristine, procarbazine, prednisone; OEPA, vincristine, etoposide, prednisone, doxorubicin; OPPA, vincristine, procarbazine, prednisone, doxorubicin.